Actualités

Fears about a looming patent cliff have dragged on the shares.

While Wall Street fretted over the future of its biggest blockbuster, a pair of new drugs were already showing the company's next act was well underway.

The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

NeoGenomics (NEO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

RLTs were a hot topic at ASCO 2026, but experts note that certain limitations must be addressed to facilitate their widespread use in cancer care.

While investors fixate on the pipeline, a powerful and accelerating profit stream from its Sanofi collaboration is quietly reshaping the company's financial core.

Pfizer’s recent drug approvals give the company something to build on, with shareholders looking for evidence that cost cuts and newer medicines can keep the 2026 earnings outlook on track.

The market is focused on Amgen's legacy drugs, but one number shows a new, faster-growing core business is already taking over.

Investing.com -- Kardigan Inc. shares rose iver 27% roughly one hour into its Nasdaq debut on Thursday, after the heart-health focused biotech raised $400 million in an initial public offering.

Bristol-Myers Squibb (BMY) stock is drawing attention after recent trading performance, with shares closing at US$55.28. Investors are weighing this level against the company’s mixed growth profile across revenue, earnings and longer term returns. See our latest analysis for Bristol-Myers Squibb. Recent trading has been a bit soft, with a 30 day share price return down 3.54% and a 90 day return down 4.87%. However, the 1 year total shareholder return of 23.92% shows that longer term holders...

Bristol Myers Squibb (NYSE:BMY) reported positive Phase III SUCCESSOR-2 trial results in multiple myeloma at a major medical conference. The company highlighted early clinical success for a new CAR T-cell therapy targeting blood cancers. Bristol Myers Squibb appointed a new General Manager to lead its operations across the Gulf region. Bristol Myers Squibb is a large biopharmaceutical company with a long-standing focus on oncology and hematology treatments. The fresh readout from the...

The latest trading day saw Bristol Myers Squibb (BMY) settling at $55.28, representing a -1.14% change from its previous close.

CYTK has gained 18.4% YTD as Myqorzo's FDA approval, early launch momentum, and expanding market opportunities fuel investor interest.

IMCR is seeing strong Kimmtrak sales growth and pursuing label expansion studies that could broaden its reach across melanoma treatments.

Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.

Bristol Myers Squibb (BMS) has revealed clinical data for two pipeline candidates in multiple myeloma (MM) at the European Hematology Association Congress (EHA) 2026, held from June 11–14. While the drugmaker already has multiple therapies approved for the type of blood cancer, BMS is hoping to expand its presence in the market by addressing certain…

Bristol Myers eyes growth from Camzyos as the FDA reviews its use in adolescents with obstructive HCM, expanding the drug's market reach.

Edgewise Therapeutics shares yo-yoed Tuesday as investors compared the results of its experimental heart disease treatment to approved drugs.

They have a habit of consistently raising their payouts.

Most Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) owners assume they are buying broad market diversification. The latest Schwab fact sheet tells a different story. SCHD’s top 10 holdings now account for 41% of the fund’s $71.6 billion in net assets, well above the roughly 30% top-10 weight typical of large-cap dividend peers. SCHD still earns ... SCHD Now Concentrates 42 Percent of Your Money in Just 10 Stocks. Here Is Who Should Still Own It

With the 10-Year Treasury yielding 4.48% and the Fed signaling more cuts ahead, income investors are hunting for yield that compounds. Bristol Myers Squibb (NYSE:BMY) offers a 4.39% yield backed by 94 consecutive years of dividend payments. The pharma giant is rebuilding around a Growth Portfolio (Eliquis, Camzyos, Breyanzi) while legacy drugs face generic erosion. ... A Dramatic Shift in Fed Policy Just Unlocked a New Era for Bristol Myers Squibb

The S&P 500 index is removing Pool Corp and Campbell Soup, replacing them with Marvell Technology and Flex. The team discusses what this means for investors.

Bristol Myers Squibb has a well-above-market yield of 4.5% and it appears reasonably safe.

BMY's growth portfolio now drives more than half of revenues, with strong gains from Reblozyl, Breyanzi and Cobenfy helping offset legacy drug declines.

Bristol Myers Squibb (NYSE:BMY) is rolling out an AI driven overhaul of its procurement operations, using tools designed to shorten sourcing timelines and reshape internal buying processes. The company is also expanding its oncology footprint through a new non exclusive clinical collaboration with Arcus Biosciences that focuses on late stage cancer drug trials. These developments come alongside earlier attention on product approvals, clinical milestones, and access programs, which have...

Bristol Myers Squibb (BMY) closed at $56.87 in the latest trading session, marking a +2.28% move from the prior day.

"Productivity initiatives" could prove key in maintaining this pharma company's decades-long dividend growth streak.

Takeda said Thursday its AI-designed psoriasis pill, zasocitinib, easily beat Bristol's Sotyktu in a head-to-head study.

The results support Takeda’s long-held belief in zasocitinib’s superiority and could help it gain a commercial advantage over Bristol’s therapy.